OverviewSuggest Edit

Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
TypePublic
Founded1991
HQSalt Lake City, US
Websitemyriad.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Jun 2019)2,600(+9%)
Job Openings74
Revenue (FY, 2020)$638.6 M(-24%)
Share Price (Sept 2020)$12.1 (-4%)
Cybersecurity ratingDMore

Key People/Management at Myriad Genetics

Bryan Riggsbee

Bryan Riggsbee

Interim President and CEO, Chief Financial Officer
Patrick Burke

Patrick Burke

Executive Vice President, Emerging Products
Raymond Francot

Raymond Francot

Executive Vice President, International Operations
Bryan Dechairo

Bryan Dechairo

Officer, Executive Vice President, Development
Clivetty Martinez

Clivetty Martinez

Chief Compliance Officer
Nicole Lambert

Nicole Lambert

Group President, Myriad Oncology, Myriad Women’s Health and Myriad International
Show more

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, US (HQ)
320 Wakara Way
Austin, US
3300 Duval Rd
South San Francisco, US
180 Kimball Way
South San Francisco, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
13 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Show all (13)

Myriad Genetics Financials and Metrics

Myriad Genetics Revenue

Myriad Genetics's revenue was reported to be $638.60 m in FY, 2020
USD

Revenue (FY, 2020)

638.6m

Net income (FY, 2020)

(199.6m)

EBIT (FY, 2020)

(231.7m)

Market capitalization (23-Sept-2020)

900.2m

Closing stock price (23-Sept-2020)

12.1

Cash (30-Jun-2020)

163.7m

EV

1.0b
Myriad Genetics's current market capitalization is $900.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

771.4m772.6m851.1m638.6m

Revenue growth, %

4%0%10%

Cost of goods sold

171.2m177.2m201.0m

Gross profit

600.2m595.4m650.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

190.2m194.0m193.5m202.3m216.8m216.6m186.3m195.1m

Cost of goods sold

43.0m44.4m44.1m49.7m52.1m48.6m49.7m49.6m

Gross profit

147.2m149.6m149.4m152.6m164.7m168.0m136.6m145.5m

Gross profit Margin, %

77%77%77%75%76%78%73%75%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.4m110.9m93.2m163.7m

Accounts Receivable

105.6m98.3m133.9m68.1m

Prepaid Expenses

12.7m9.4m16.6m

Inventories

42.2m34.3m31.4m29.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

87.9m88.7m97.4m93.3m90.6m84.9m89.9m81.2m

Accounts Receivable

113.2m121.1m123.7m119.1m116.6m142.6m4.8m118.3m102.5m

Prepaid Expenses

9.5m9.8m10.1m11.5m12.5m11.3m14.0m16.2m

Inventories

38.9m38.2m33.4m35.9m33.3m31.9m28.1m28.1m30.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

21.8m131.1m4.6m(199.5m)

Depreciation and Amortization

48.3m54.4m73.0m

Inventories

(1.2m)7.9m8.0m1.6m

Accounts Payable

(3.0m)4.0m1.1m(10.7m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

81.1m113.2m124.6m(700.0k)1.9m8.8m(20.6m)(28.9m)(144.1m)

Depreciation and Amortization

13.2m26.3m39.3m18.3m36.3m54.6m18.2m36.4m54.3m

Inventories

3.3m4.1m8.9m3.5m6.1m7.4m3.1m2.6m

Accounts Payable

400.0k3.0m(2.0m)(8.4m)(300.0k)(8.1m)(9.3m)(11.3m)(2.1m)
USDFY, 2017

Revenue/Employee

321.4k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.6 x
Show all financial metrics

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patients Tested to Date

2 m3 m3 m

Products

11

Publications to Date

1 k

Countries

143
Show all operating metrics

Myriad Genetics Acquisitions / Subsidiaries

Company NameDateDeal Size
Myriad Women’s HealthMay 29, 2018$408.60 m
Myriad NeuroscienceAugust 03, 2016$351.60 m
Sividon DiagnosticsMay 31, 2016$56 m
Privatklinik Dr. Robert SchindlbeckFebruary 27, 2015$20.10 m
Crescendo BioscienceFebruary 04, 2014$270 m
Rules-Based MedicineApril 27, 2011$80 m
Javelin PharmaceuticalsDecember 18, 2009$95 m
NaturNorth TechnologiesApril 10, 2008
AssureRx Canada, Ltd
Assurex Health, Inc.
Show more

Myriad Genetics Cybersecurity Score

Cybersecurity ratingPremium dataset

D

60/100

SecurityScorecard logo

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing

Myriad Genetics Online and Social Media Presence

Embed Graph

Myriad Genetics News and Updates

Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Data Bridge Market Research has added a new report titled Global Liquid Biopsy Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Liqu…

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. EST on Feb…

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal second-quarter 2020, provided an update on recent business highlights…

MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action

NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. from September 2, 2016 through August 13, 2019, inclusive (the "Class Period") of the important November 26, 2019 lead plaintiff...

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

SALT LAKE CITY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) to help phy…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN

NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) and certain of its officers. The class action, filed in United States District Court, for the District of...
Show more

Myriad Genetics Blogs

When Gray Days Lead to “the Blues”

Fall slump. The winter blahs. Is it almost spring? Weather can have an impact on our daily mood and feelings. For… The post When Gray Days Lead to “the Blues” appeared first on Myriad Genetics, Inc..

3 Tips to Help You Prevent Breast Cancer

The post 3 Tips to Help You Prevent Breast Cancer appeared first on Myriad Genetics, Inc..

The Importance of Hereditary Cancer Testing for Patients with Pancreatic Cancer

Pancreatic cancer is the third leading cause of death due to cancer.1 Approximately 56,500 people, or 1 in 64, will be diagnosed… The post The Importance of Hereditary Cancer Testing for Patients with Pancreatic Cancer appeared first on Myriad Genetics, Inc..
Show more

Myriad Genetics Frequently Asked Questions

  • When was Myriad Genetics founded?

    Myriad Genetics was founded in 1991.

  • Who are Myriad Genetics key executives?

    Myriad Genetics's key executives are Bryan Riggsbee, Patrick Burke and Raymond Francot.

  • How many employees does Myriad Genetics have?

    Myriad Genetics has 2,600 employees.

  • What is Myriad Genetics revenue?

    Latest Myriad Genetics annual revenue is $638.6 m.

  • What is Myriad Genetics revenue per employee?

    Latest Myriad Genetics revenue per employee is $245.6 k.

  • Who are Myriad Genetics competitors?

    Competitors of Myriad Genetics include Progenity, Foundation Medicine and Genomic Health.

  • Where is Myriad Genetics headquarters?

    Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.

  • Where are Myriad Genetics offices?

    Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.

  • How many offices does Myriad Genetics have?

    Myriad Genetics has 13 offices.